Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Oates

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The Journal of Urology|December 14, 2004
Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductaseArun K Changolkar, Joseph A Hypolite, Michael Disanto, et al.
Diabetes|April 29, 2006
Elevated activity of transcription factor nuclear factor of activated T-cells 5 (NFAT5) and diabetic nephropathyBingmei Yang, Andrea D Hodgkinson, Peter J Oates, et al.
The Journal of Biological Chemistry|April 12, 2020
Restoring mitochondrial superoxide levels with elamipretide (MTP-131) protects <i>db/db</i> mice against progression of diabetic kidney diseaseSatoshi Miyamoto, Guanshi Zhang, David Hall, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 5, 2002
Aldose reductase activation is a key component of myocardial response to ischemiaYuying C Hwang, Sanai Sato, Jen-Yue Tsai, et al.
Diabetes Care|August 29, 2006
Decline in neurophysiological function after 7 years in an adolescent diabetic cohort and the role of aldose reductase gene polymorphismsKeerthi Thamotharampillai, Albert K F Chan, Bruce Bennetts, et al.
Antioxidants & Redox Signaling|July 24, 2009
Early neural and vascular dysfunctions in diabetic rats are largely sequelae of increased sorbitol oxidationYasuo Ido, Jens R Nyengaard, Kathy Chang, et al.
Journal of Clinical Pharmacology|March 12, 2010
Pharmacokinetics, pharmacodynamics, tolerability, and safety of a novel sorbitol dehydrogenase inhibitor in healthy participantsZohar Landau, Mark J Novotny, Gregory M Preston, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2002
SAR and species/stereo-selective metabolism of the sorbitol dehydrogenase inhibitor, CP-470,711Margaret Y Chu-Moyer, William E Ballinger, David A Beebe, et al.
Bioorganic & Medicinal Chemistry|September 3, 2003
Design and synthesis of a novel family of triazine-based inhibitors of sorbitol dehydrogenase with oral activity: 1-[4-[3R,5S-dimethyl-4-(4-methyl-[1,3,5]triazin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl]-(R) ethanolBanavara L Mylari, Gregory J Withbroe, David A Beebe, et al.
Journal of Medicinal Chemistry|September 20, 2002
A sorbitol dehydrogenase inhibitor of exceptional in vivo potency with a long duration of action: 1-(R)-[4-[4-(4,6-dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl]ethanolBanavara L Mylari, Peter J Oates, William J Zembrowski, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The Journal of Urology|December 14, 2004
Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductaseArun K Changolkar, Joseph A Hypolite, Michael Disanto, et al.
Diabetes|April 29, 2006
Elevated activity of transcription factor nuclear factor of activated T-cells 5 (NFAT5) and diabetic nephropathyBingmei Yang, Andrea D Hodgkinson, Peter J Oates, et al.
The Journal of Biological Chemistry|April 12, 2020
Restoring mitochondrial superoxide levels with elamipretide (MTP-131) protects <i>db/db</i> mice against progression of diabetic kidney diseaseSatoshi Miyamoto, Guanshi Zhang, David Hall, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 5, 2002
Aldose reductase activation is a key component of myocardial response to ischemiaYuying C Hwang, Sanai Sato, Jen-Yue Tsai, et al.
Diabetes Care|August 29, 2006
Decline in neurophysiological function after 7 years in an adolescent diabetic cohort and the role of aldose reductase gene polymorphismsKeerthi Thamotharampillai, Albert K F Chan, Bruce Bennetts, et al.
Antioxidants & Redox Signaling|July 24, 2009
Early neural and vascular dysfunctions in diabetic rats are largely sequelae of increased sorbitol oxidationYasuo Ido, Jens R Nyengaard, Kathy Chang, et al.
Journal of Clinical Pharmacology|March 12, 2010
Pharmacokinetics, pharmacodynamics, tolerability, and safety of a novel sorbitol dehydrogenase inhibitor in healthy participantsZohar Landau, Mark J Novotny, Gregory M Preston, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2002
SAR and species/stereo-selective metabolism of the sorbitol dehydrogenase inhibitor, CP-470,711Margaret Y Chu-Moyer, William E Ballinger, David A Beebe, et al.
Bioorganic & Medicinal Chemistry|September 3, 2003
Design and synthesis of a novel family of triazine-based inhibitors of sorbitol dehydrogenase with oral activity: 1-[4-[3R,5S-dimethyl-4-(4-methyl-[1,3,5]triazin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl]-(R) ethanolBanavara L Mylari, Gregory J Withbroe, David A Beebe, et al.
Journal of Medicinal Chemistry|September 20, 2002
A sorbitol dehydrogenase inhibitor of exceptional in vivo potency with a long duration of action: 1-(R)-[4-[4-(4,6-dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl]ethanolBanavara L Mylari, Peter J Oates, William J Zembrowski, et al.
Pageof 3